Water Soluble Cholesterol Derivatives

- AFFYMETRIX, INC.

Four novel water soluble cholesterol derivative compounds are disclosed. These compounds have various applications in studies of membrane proteins, including drug screening and studies of receptor stability and folding. In one aspect the water soluble cholesterol derivatives disclosed may be used to replace cholesterol in micelle-solubilized membrane protein preparations.

Skip to: Description  ·  Claims  · Patent History  ·  Patent History
Description
REFERENCES TO RELATED APPLICATIONS

The present application is a continuation of U.S. patent application Ser. No. 12/494,159, filed Jun. 29, 2009, which claims priority to U.S. Provisional Patent Application Ser. No. 61/082,114, filed on Jul. 18, 2008, which are hereby incorporated herein by reference in their entirety for all purposes.

STATEMENT OF FEDERALLY SPONSORED RESEARCH

This invention was made with government support under Small Business Innovation Research (SBIR) Program grant number R43MH081379 awarded by the National Institutes of Health. The government has certain rights in the invention.

FIELD OF THE INVENTION

The present invention relates generally to water-soluble derivatives of cholesterol and methods for their synthesis and use.

BACKGROUND OF THE INVENTION

In order to be fully functional, many cellular receptors and other membrane proteins require interactions with cholesterol within the lipid bilayer. Therefore, when reconstituting these proteins for in vitro biochemical and structural studies, it is desirable to mimic the native bilayer as closely as possible. This can be accomplished by adding the appropriate lipids and cholesterol to micelle-solubilized membrane protein preparations. One obstacle however, is that cholesterol is notoriously difficult to solubilize under the micellar conditions typically used for membrane protein solubilization. In the present invention, four novel water soluble cholesterol analogs are disclosed which have various applications in studies of membrane proteins.

SUMMARY OF THE INVENTION

We have prepared four water-soluble cholesterol derivatives depicted in the Figures. FIG. 1A is Cholesterol-β-tetrasaccharide (1), FIG. 1B is Cholesterol-α-tetrasaccharide (2), and FIG. 1C is Cholesterol-β-sulfated maltoside (3). FIG. 1D is Diosgenin-β-tetrasaccharide (4). In one embodiment, the compounds are made by multi-step chemical synthesis from commercial cholesterol or diosgenin (other steroids are potential substrates and are denoted as ‘cholesterol derivative’) and maltose.

In preferred aspects, the tetrasaccharide is prepared via selective coupling of two differentiated units of a protected maltose. For each compound a final coupling step between the cholesterol derivative and the saccharide is required. Descriptions of alpha and beta are descriptors of the anomeric linkage between the cholesterol derivative and the first sugar. Each compound can be made on a scale of up to 5 g and they are soluble up to 5% w/v in water.

BRIEF DESCRIPTION OF THE DRAWING

The accompanying drawing, which is incorporated in and forms a part of this specification, illustrates embodiments of the invention and, together with the description, serves to explain the invention:

FIG. 1A shows the structure of Cholesterol-β-tetrasaccharide (1). FIG. 1B shows the structure of Cholesterol-α-tetrasaccharide (2). FIG. 1C shows the structure of Cholesterol-β-sulfated maltoside (3). FIG. 1D shows the structure of Diosgenin-β-tetrasaccharide (4).

DETAILED DESCRIPTION OF THE INVENTION General

The present invention has many embodiments and relies on many patents, applications and other references for details known to those of the art. Therefore, when a patent, application, or other reference is cited or repeated below, it should be understood that it is incorporated by reference in its entirety for all purposes as well as for the proposition that is recited.

As used in this application, the singular form “a,” “an,” and “the” include plural references unless the context clearly dictates otherwise. For example, the term “an agent” includes a plurality of agents, including mixtures thereof.

DEFINITIONS

Cholesterol is a lipid compound with a molecular formula C27H46O, consisting of three structurally distinct regions: i) a rigid sterol ring, ii) a flexible alkyl chain, together forming the hydrophobic portion of the molecule, and iii) 3β-hydroxyl moiety, which is the only polar group in cholesterol and gives the molecule its amphiphatic character. Cholesterol is an essential component of cell membranes in all eukaryotes, with crucial roles in membrane organization, dynamics, function and sorting.

Cholesterol is found distributed non-randomly in domains and pools in biological membranes, and has been reported to modulate conformation (and hence function) of integral membrane proteins, either through a specific molecular interactions, or through alterations in the membrane physical properties induced by the presence of cholesterol.

An example of a membrane protein family regulated by cholesterol is the seven transmembrane domain G-protein coupled receptors (GPCRs). The GPCR family has over 800 members, representing approximately 2% of total proteins encoded by the human genome. GPCRs have diverse signaling functions, mediating responses to both endogenous and exogenous ligands via recruitment and activation of heterotrimeric G-proteins to the cytoplasmic side of the cell membrane. GPCR-activated heterotrimeric G-proteins in turn regulate a multitude of physiological processes ranging from neurotransmission and cellular differentiation and growth to inflammatory and olfactory responses. Therefore, GPCRs represent major targets for the development of new drugs.

The term liposome, as used in this application, refers to a vesicular structure composed of a lipid bilayer separating an aqueous internal compartment from the bulk aqueous phase. Liposomes can be composed of naturally-derived phospholipids with mixed lipid chains, or of pure surfactant components such as DOPE (dioleoylphosphatidylethanolamine). The term micelle, as used in this application, refers to closed lipid monolayers with a fatty acid core and polar surface, or for an inverted micelle, a polar core with fatty acids on the surface. Due to their unique structure, both liposomes and micelles have been used in vitro studies of protein function as well as drug delivery.

The term water-soluble cholesterol derivative, as used in this application, refers to cholesterol analogs containing a water-soluble head group or moiety.

Water-Soluble Cholesterol Derivatives

Commercially available water-soluble cholesterol derivatives, such as cholesterol hemisuccinate and cholesterol sulfate, have been used as cholesterol substitutes in studies of membrane protein function and structure. These cholesterol analogs contain anionic head groups, making them more suitable for micellar membrane protein preparations. However, cholesterol hemisuccinate and cholesterol sulfate remain difficult to solubilize in detergent micelles, and their anionic head groups make them not biochemically optimal for in vitro protein studies. Therefore, there remains a need for the development of water-soluble cholesterol derivatives that can be better utilized in biochemical and structural studies of membrane proteins.

To address this issue, we have synthesized novel, water-soluble cholesterol derivatives that can be used to enhance the solubility and functionality of micelle-solubilized membrane proteins for biochemical and structural studies. These compounds will likely be useful in other applications that benefit from abundant quantities of pure and properly-folded membrane proteins (ie, GPCRs), including drug screening and studies of receptor stability and folding.

In a preferred aspect, the compounds are made by multi-step chemical synthesis from commercial cholesterol or diosgenin (other steroids are potential substrates and are denoted as ‘cholesterol derivative’) and maltose.

In preferred aspects, the tetrasaccharide is prepared via selective coupling of two differentiated units of a protected maltose. For each compound a final coupling step between the cholesterol derivative and the saccharide is required. Descriptions of alpha and beta are descriptors of the anomeric linkage between the cholesterol derivative and the first sugar. Each compound can be made on a scale of up to 5 g and they are soluble up to 5% w/v in water.

CONCLUSION

It is to be understood that the above description is intended to be illustrative and not restrictive. Many variations of the invention will be apparent to those of skill in the art upon reviewing the above description. The scope of the invention should be determined with reference to the appended claims, along with the full scope of equivalents to which such claims are entitled. All cited references, including patent and non-patent literature, are incorporated herewith by reference in their entireties for all purposes.

Claims

1. Cholesterol-β-tetrasaccharide according to Formula I:

2. Cholesterol-α-tetrasaccharide according to Formula II:

3. Cholesterol-β-sulfated maltoside according to Formula III, wherein X is selected from the group consisting of Me3NH, NH4, and Na:

4. Diosgenin-β-tetrasaccharide according to Formula IV:

5. A composition comprising the cholesterol-β-tetrasaccharide according to claim 1.

6. A composition comprising the cholesterol-α-tetrasaccharide according to claim 2.

7. A composition comprising the cholesterol-β-sulfated maltoside according to claim 3.

8. A composition comprising the diosgenin-β-tetrasaccharide according to claim 4.

9. A method of synthesizing the cholesterol-β-tetrasaccharide according to claim 1, wherein the synthesis begins with materials comprising cholesterol and maltose.

10. A method of synthesizing the cholesterol-α-tetrasaccharide according to claim 2, wherein the synthesis begins with materials comprising cholesterol and maltose.

11. A method of synthesizing the cholesterol-β-sulfated maltoside according to claim 3, wherein the synthesis begins with materials comprising cholesterol and maltose.

12. A method of synthesizing the diosgenin-β-tetrasaccharide according to claim 4, wherein the synthesis begins with materials comprising diosgenin and maltose.

13. A method of reconstituting membrane proteins in a lipid bilayer, comprising: and mixing the membrane protein and the at least one cholesterol derivative to reconstitute membrane protein suitable for in vitro biochemical and structural studies.

providing membrane protein;
providing at least one cholesterol derivative selected from the group consisting of:

14. The method according to claim 13, wherein the membrane protein is a G-protein coupled receptor (GPCR).

15. The method according to claim 13, wherein the membrane protein is a transmembrane protein.

Patent History
Publication number: 20120041182
Type: Application
Filed: Oct 24, 2011
Publication Date: Feb 16, 2012
Applicant: AFFYMETRIX, INC. (Santa Clara, CA)
Inventors: Lijun M. Huang (Waterville, OH), Benjamin R. Travis (Maumee, OH)
Application Number: 13/280,127
Classifications
Current U.S. Class: Glycoprotein, E.g., Mucins, Proteoglycans, Etc. (530/395); Cyclopentanohydrophenanthrene Ring System (536/5); Oxygen Containing Six-membered Hetero Ring (e.g., Oxathiane, Etc.) (536/6)
International Classification: C07K 14/00 (20060101); C07G 3/00 (20060101); C07J 41/00 (20060101);